Zacks: Brokerages Anticipate Endo International plc (ENDP) Will Post Earnings of $0.54 Per Share

Analysts expect Endo International plc (NASDAQ:ENDP) (TSE:ENL) to post earnings per share of $0.54 for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Endo International’s earnings. The highest EPS estimate is $0.60 and the lowest is $0.49. Endo International reported earnings of $0.93 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 41.9%. The firm is scheduled to issue its next earnings report on Tuesday, August 14th.

According to Zacks, analysts expect that Endo International will report full year earnings of $2.36 per share for the current year, with EPS estimates ranging from $2.24 to $2.48. For the next year, analysts anticipate that the company will post earnings of $2.51 per share, with EPS estimates ranging from $2.29 to $2.95. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Endo International.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Tuesday, May 8th. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.12. Endo International had a positive return on equity of 143.46% and a negative net margin of 75.58%. The firm had revenue of $700.53 million during the quarter, compared to the consensus estimate of $691.94 million. During the same quarter in the prior year, the company earned $1.23 EPS. The firm’s revenue for the quarter was down 32.5% compared to the same quarter last year.



Several brokerages recently weighed in on ENDP. Mizuho downgraded Endo International from a “buy” rating to a “neutral” rating and decreased their target price for the company from $12.00 to $7.00 in a research note on Wednesday, April 4th. BidaskClub downgraded Endo International from a “sell” rating to a “strong sell” rating in a research note on Friday, April 6th. Zacks Investment Research upgraded Endo International from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 1st. Canaccord Genuity set a $7.00 target price on Endo International and gave the company a “hold” rating in a research note on Wednesday, February 21st. Finally, Barclays decreased their target price on Endo International from $15.00 to $10.00 and set an “equal weight” rating for the company in a research note on Friday, February 23rd. Three analysts have rated the stock with a sell rating, seventeen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average target price of $9.40.

Hedge funds have recently made changes to their positions in the business. Paloma Partners Management Co bought a new stake in shares of Endo International in the 4th quarter worth approximately $122,000. Oakbrook Investments LLC bought a new stake in shares of Endo International in the 4th quarter worth approximately $133,000. Xact Kapitalforvaltning AB bought a new stake in shares of Endo International in the 4th quarter worth approximately $157,000. Elkfork Partners LLC bought a new stake in shares of Endo International in the 4th quarter worth approximately $194,000. Finally, Nisa Investment Advisors LLC bought a new stake in shares of Endo International in the 4th quarter worth approximately $236,000. Institutional investors own 98.38% of the company’s stock.

NASDAQ:ENDP traded up $0.23 during mid-day trading on Friday, hitting $6.18. 150,538 shares of the company’s stock traded hands, compared to its average volume of 5,113,884. Endo International has a 12 month low of $5.27 and a 12 month high of $14.15. The company has a market cap of $1.34 billion, a price-to-earnings ratio of 1.61 and a beta of 0.34. The company has a quick ratio of 0.88, a current ratio of 1.06 and a debt-to-equity ratio of -1,161.84.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply